Cancer treatment with immune checkpoint inhibitors may lead to thyroid dysfunction

March 31, 2020

WASHINGTON--Thyroid dysfunction following cancer treatment with new treatments called immune checkpoint inhibitors is more common than previously thought, according to research that was accepted for presentation at ENDO 2020, the Endocrine Society's annual meeting, and will be published in a special supplemental section of the Journal of the Endocrine Society.

Cancer immunotherapy, particularly treatment with immune checkpoint inhibitors, has become an important part of treating some types of cancer and offers some patients sustained remissions. Immune checkpoint inhibitors are drugs that take the 'brakes' off the immune system, which helps it recognize and attack cancer cells. Immune checkpoint inhibitors are approved to treat some patients with a variety of cancers, including breast, bladder, cervical, colon, head and neck, liver, lung, skin, stomach and rectal cancers.

Along with the benefits of these treatments, possible side effects include immune-related adverse events, when the immune system attacks normal, noncancerous cells. One of the more common, but mild, side effects is abnormal thyroid levels, particularly hypothyroidism (an underactive thyroid).

"It was unclear to what extent this side effect occurred outside the clinical trial setting and so we used information from electronic health records to determine how common it was in practice," said lead researcher Zoe Quandt, M.D., of the University of California, San Francisco in San Francisco, Calif. "Understanding who gets these immune-related adverse events, why they get them and what impact they have on response to therapy is an essential part of optimizing our use of immune checkpoint inhibitors."

The researchers analyzed electronic health record data from the University of California, San Francisco on every patient who had received immune checkpoint inhibitors for treatment of cancer between 2012 and 2018.

They excluded anyone with thyroid cancer, whether or not that was the indication for the immune checkpoint inhibitor, or pre-existing thyroid disease. For the remaining 1,146 patients, they looked for those who had some type of thyroid dysfunction--either abnormal levels of thyroid hormones or a prescription for thyroid medication. Melanoma was the most common cancer treated (32%), followed by non-small cell lung cancer (13%).

Overall, 19% of subjects exposed to immune checkpoint inhibitors developed thyroid dysfunction. In contrast, a review of clinical trials found a much lower rate--6.6% of immune checkpoint inhibitor patients developed hypothyroidism, and 2.9% had hyperthyroidism, or an overactive thyroid.

The new study found thyroid problems varied by the type of cancer. The rate of thyroid dysfunction ranged from 10% of patients with the brain tumor glioblastoma to 40% in renal cell cancer, a type of kidney cancer. While there was no significant association between thyroid dysfunction and specific immune checkpoint inhibitors, thyroid dysfunction was more common in patients who received a combination of nivolumab (Opdivo) and ipilimumab (Yervoy) (31%) compared with either pembrolizumab (Keytruda) (18%), nivolumab (18%) or ipilimumab (15%) alone.
The Endocrine Society canceled its annual meeting, ENDO 2020, amid concerns about COVID-19. Visit our Journal of the Endocrine Society.

Endocrinologists are at the core of solving the most pressing health problems of our time, from diabetes and obesity to infertility, bone health, and hormone-related cancers. The Endocrine Society is the world's oldest and largest organization of scientists devoted to hormone research and physicians who care for people with hormone-related conditions.

The Society has more than 18,000 members, including scientists, physicians, educators, nurses and students in 122 countries. To learn more about the Society and the field of endocrinology, visit our site at Follow us on Twitter at @EndoMedia.

The Endocrine Society

Related Cancer Articles from Brightsurf:

New blood cancer treatment works by selectively interfering with cancer cell signalling
University of Alberta scientists have identified the mechanism of action behind a new type of precision cancer drug for blood cancers that is set for human trials, according to research published in Nature Communications.

UCI researchers uncover cancer cell vulnerabilities; may lead to better cancer therapies
A new University of California, Irvine-led study reveals a protein responsible for genetic changes resulting in a variety of cancers, may also be the key to more effective, targeted cancer therapy.

Breast cancer treatment costs highest among young women with metastic cancer
In a fight for their lives, young women, age 18-44, spend double the amount of older women to survive metastatic breast cancer, according to a large statewide study by the University of North Carolina at Chapel Hill.

Cancer mortality continues steady decline, driven by progress against lung cancer
The cancer death rate declined by 29% from 1991 to 2017, including a 2.2% drop from 2016 to 2017, the largest single-year drop in cancer mortality ever reported.

Stress in cervical cancer patients associated with higher risk of cancer-specific mortality
Psychological stress was associated with a higher risk of cancer-specific mortality in women diagnosed with cervical cancer.

Cancer-sniffing dogs 97% accurate in identifying lung cancer, according to study in JAOA
The next step will be to further fractionate the samples based on chemical and physical properties, presenting them back to the dogs until the specific biomarkers for each cancer are identified.

Moffitt Cancer Center researchers identify one way T cell function may fail in cancer
Moffitt Cancer Center researchers have discovered a mechanism by which one type of immune cell, CD8+ T cells, can become dysfunctional, impeding its ability to seek and kill cancer cells.

More cancer survivors, fewer cancer specialists point to challenge in meeting care needs
An aging population, a growing number of cancer survivors, and a projected shortage of cancer care providers will result in a challenge in delivering the care for cancer survivors in the United States if systemic changes are not made.

New cancer vaccine platform a potential tool for efficacious targeted cancer therapy
Researchers at the University of Helsinki have discovered a solution in the form of a cancer vaccine platform for improving the efficacy of oncolytic viruses used in cancer treatment.

American Cancer Society outlines blueprint for cancer control in the 21st century
The American Cancer Society is outlining its vision for cancer control in the decades ahead in a series of articles that forms the basis of a national cancer control plan.

Read More: Cancer News and Cancer Current Events is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to